Pharmaceutical

Gilead and MSD to advance once-weekly HIV treatment to Phase III

The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

Oct 24, 2024 - 04:00
Gilead and MSD to advance once-weekly HIV treatment to Phase III
The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.
Read the original article

Tags:

Previous Article

A slow start for self-amplifying mRNA vaccines

Next Article

Pharma companies must adapt to keep pace with AI developments, say experts

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Democrats press government to extend free Covid-19 tests indefinitely

Democrats press government to extend free Covid-19 test...

Jul 14, 2023

FDA issues draft guidance on stimulant use disorder drug development

FDA issues draft guidance on stimulant use disorder dru...

Oct 5, 2023

Gilead Sciences to exclusively license Nurix Therapeutics’ protein degrader

Gilead Sciences to exclusively license Nurix Therapeuti...

Mar 21, 2023